NEO-1132

N/A

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameNEO-1132
Drug Alias NameNEO-1132
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionBromodomain-containing protein 4 inhibitorsp300-CBP transcription factors inhibitors
Targetsp300-CBP transcription factorsBromodomain-containing protein 4
Therapy Area/IndicationsProstatic NeoplasmsLymphoma, Large B-Cell, DiffuseLeukemia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesEpigenetixNeomed Institute
China Registration ClassN/A

Develop Information

Active CompaniesEpigenetixNeomed Institute
Inactive CompaniesN/A
Active IndicationsProstatic NeoplasmsLymphoma, Large B-Cell, DiffuseLeukemia
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A